01856nas a2200361 4500000000100000008004100001260001300042653002800055653001800083653001100101653002500112653001200137653002400149653002500173653002500198653002100223653003500244653005000279653000900329100001800338700001200356700001500368700001000383700001900393700001100412700001400423700001400437245007800451300001100529490000800540520093200548022001401480 2007 d c2007 Dec 10 aAngiogenesis Inhibitors 10 aBlood Vessels 10 aHumans 10 aImmunohistochemistry 10 aleprosy 10 aLeprosy, Borderline 10 aLeprosy, lepromatous 10 aLeprosy, Tuberculoid 10 aMicrocirculation 10 aNeovascularization, Pathologic 10 aPlatelet Endothelial Cell Adhesion Molecule-1 10 aSkin 1 aBhandarkar SS 1 aCohen C 1 aKuruvila M 1 aRea T 1 aMackelfresh JB 1 aLee DJ 1 aModlin RL 1 aArbiser J 00 aAngiogenesis in cutaneous lesions of leprosy: implications for treatment. a1527-9 0 v143 3 aOBJECTIVE: To examine the potential role of angiogenesis in leprosy.
DESIGN: Immunohistochemical analysis of leprosy lesions.
SETTING: Department of Dermatology, Venereology, and Leprology, Kasturba Medical College; Division of Dermatology, University of California at Los Angeles; and Departments of Dermatology and Pathology, Emory University.
PATIENTS: Thirty-two cutaneous lesions that represented the spectrum of leprosy were obtained from 32 patients.
MAIN OUTCOME MEASURE: CD31 microvessel counts.
RESULTS: The mean CD31 microvessel count in borderline tuberculoid, midborderline, and lepromatous leprosy lesions was significantly higher than in indeterminate leprosy lesions.
CONCLUSIONS: Increased bacterial load is associated with increased angiogenesis. Angiogenesis inhibitors may be of benefit in the treatment of leprosy.
a1538-3652